We also aimed to investigate whether BPF induces apoptosis via MEK-ERK pathway in Ba/F3 cells transformed with the BCR-ABL T315I mutant that exhibits resistance to BCR-ABL inhibitors and to verify that BPF is an effective CML therapeutic agent with a novel mechanism. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.